COPENHAGEN, MAY 22, 2017 – AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced three new board members.
Joining AntibioTx board of directors are Stig Loekke Pedersen, Jutta Heim and Ole Skov join the board of directors in AntibioTx.
“We are very pleased to welcome such recognized business and science leaders to AntibioTx”, said Rasmus Toft-Kehler, CEO of AntibioTx and added “These profiles bring a diverse set of knowledge bases to AntibioTx – we are privileged that capacities with such track records join the team to achieve our vision”
Read more about our board of directors here
This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.
